Dinaciclib

Dinaciclib

SCHEMBL15637863

CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CDK1CDK2CDK5CDK9

The experimentally established mechanism targets of Dinaciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 known ✓ P24941 12/20 1.00
CDK9 known ✓ P50750 7/20 1.00
CDK5 known ✓ Q00535 5/20 1.00
CDK1 known ✓ P06493 5/20 1.00
CCNE1 P24864 6/20 1.00
CDK12 Q9NYV4 6/20 1.00
CCNK O75909 5/20 1.00
CDK7 P50613 4/20 1.00
GSK3B P49841 3/20 1.00
GSK3A P49840 2/20 1.00
TAOK1 Q7L7X3 2/20 1.00
CCNT1 O60563 2/20 1.00
CCNH P51946 2/20 1.00
MNAT1 P51948 2/20 1.00
CDK13 Q14004 2/20 1.00
CCNA2 P20248 2/20 1.00
CCNA1 P78396 2/20 1.00
CCNT2 O60583 1/20 1.00
BRD4 O60885 1/20 1.00
CCNB2 O95067 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dinaciclib SCHEMBL12048446 1.00 CDK2 (1.00) CDK2CDK9CCNE1CDK12CDK5
Dinaciclib SCHEMBL23682977 1.00 CDK2 (1.00) CDK2CDK9CCNE1CDK12CDK5
Dinaciclib SCHEMBL30176832 1.00 CDK2 (1.00) CDK2CDK9CCNE1CDK12CDK5
SCHEMBL15576865 0.92 CDK2 (0.86) CDK2CDK9CCNE1CDK12CDK5
SCHEMBL20366942 0.92 CDK2 (0.84) CDK2CDK9CCNE1CDK12CDK5
SCHEMBL23815646 0.92 CDK2 (0.84) CDK2CDK9CCNE1CDK12CDK5
SCHEMBL16366036 0.91 CDK2 (0.84) CDK2CDK9CCNE1CDK12CDK5
SCHEMBL12048531 0.91 CDK2 (1.00) CDK2CDK9CCNE1CDK12CDK5
SCHEMBL18738298 0.90 CDK2 (0.82) CDK2CDK9CCNE1CDK12CDK5
SCHEMBL12953008 0.90 CDK2 (0.81) CDK2CDK9CCNE1CDK12CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160046672-A1 STAPLING eIF4E INTERACTING PEPTIDES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-02-18 US claimed
EP-2976354-A1 STAPLING eIF4E INTERACTING PEPTIDES Agency For Science, Technology And Research (SG) 2016-01-27 EP claimed
US-20150246946-A1 PEPTIDES AND METHODS FOR TREATING CANCER AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-09-03 US claimed
EP-2904000-A1 PEPTIDES AND METHODS FOR TREATING CANCER Agency for Science, Technology and Research (SG) 2015-08-12 EP claimed
WO-2014149001-A1 STAPLING eIF4E INTERACTING PEPTIDES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-09-25 WO claimed
WO-2014055039-A1 PEPTIDES AND METHODS FOR TREATING CANCER AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-04-10 WO claimed
US-11319344-B2 Non-membrane disruptive P53 activating stapled peptides AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-05-03 US disclosed
EP-3256484-B1 NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES AGENCY SCIENCE TECH & RES (SG) 2021-06-23 EP disclosed
US-20180030090-A1 NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-02-01 US disclosed
EP-3256484-A1 NON-MEMBRANE DISRUPTIVE p53 ACTIVATING STAPLED PEPTIDES Agency For Science, Technology And Research (SG) 2017-12-20 EP disclosed
WO-2016130092-A1 NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-08-18 WO disclosed
US-20160046672-A1 STAPLING eIF4E INTERACTING PEPTIDES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-02-18 US disclosed
EP-2976354-A1 STAPLING eIF4E INTERACTING PEPTIDES Agency For Science, Technology And Research (SG) 2016-01-27 EP disclosed
WO-2015192123-A1 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO TRUSTEES OF TUFTS COLLEGE (US) 2015-12-17 WO disclosed
US-20150246946-A1 PEPTIDES AND METHODS FOR TREATING CANCER AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-09-03 US disclosed
EP-2904000-A1 PEPTIDES AND METHODS FOR TREATING CANCER Agency for Science, Technology and Research (SG) 2015-08-12 EP disclosed
WO-2014149001-A1 STAPLING eIF4E INTERACTING PEPTIDES AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-09-25 WO disclosed
WO-2014055039-A1 PEPTIDES AND METHODS FOR TREATING CANCER AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11319344-B2 Non-membrane disruptive P53 activating stapled peptides TP53, ANXA3, ANXA2 CDK2 3712/4885CDK9 4446/4885CDK5 4042/4885
US-20180030090-A1 NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES TP53, ANXA3, ANXA2 CDK2 3521/4885CDK9 4390/4885CDK5 3945/4885
US-20160046672-A1 STAPLING eIF4E INTERACTING PEPTIDES EIF4EBP1, EIF4E, EIF4G2 CDK2 2158/4885CDK9 2458/4885CDK5 1427/4885
US-20150246946-A1 PEPTIDES AND METHODS FOR TREATING CANCER TP53, MDM4, MDM2 CDK2 207/4885CDK9 595/4885CDK5 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.